Comparison of treatment and survival in European patients with a gastrointestinal stromal tumor-EURECCA ( ODR1920_015 )

The aim of this study is to describe and compare the treatment and (overall and relative) survival of patients diagnosed with Gastrointestinal stromal tumors (GIST) in European countries participating in the EURECCA consortium.

Research questions with this aim are:

1. What are the differences in treatment strategy between the countries for patients with a GIST?

2. Are there differences between European countries regarding the outcomes of GIST?

a. Overall Survival

b. Relative Survival (an estimation of the cancer specific survival by calculating observed / expected survival (matched by country, sex, age and year)

3. When using country as an instrumental variable; can we identify factors in treatment strategy of GIST which affect the clinical outcomes?

Retrospective, international cohort study. Data from all participating countries consists of cancer registry data. Specific attention will be given to a uniform definition of the variables and patient inclusion.

Males and females of 18 years or older, diagnosed with GIST (morphology code: 8936/3) between 2002 and 2018. All localizations will be included.

All patients with GIST will be identified from the cancer registries in the European countries and merged in one file.

Descriptive data of patient characteristics, tumor characteristics, treatment and survival will be

collected. These data will be compared between the different countries and stratified for high or low risk local GIST, metastatic GIST and age.

1. Characteristics of the patient and tumor from the participating countries

2. Treatment strategies for all patients, and stratified for local or metastatic and age.

3. Outcomes (overall survival, relative survival) of GIST in participating countries, for all

patients and stratified for local GIST, metastatic GIST and age.

Not stated in the register.

Comparison of treatment and survival in European patients with a gastrointestinal stromal tumor (GIST), in order to improve understanding of epidemiology and treatment of GIST in Europe.

Unfortunately, due to COVID crisis last years and adjustments of data delivery we had no opportunity to analyze the data yet. We have now completed the data collection and will start data analysis.

We expect to start and complete data analysis next year. After that, we will publish our results in a peer reviewed journal

We would like to requenst to extend the duration of contract with one year, until 15-04-2024.